长时间禁食联合低分子量肝素或华法林治疗对2-脱氧-2-[18F]-氟-D-葡萄糖PET心脏摄取的影响
174例无心脏功能障碍和/或冠心病病史及临床证据的患者在>12小时禁食后行18F-FDG PET/CT,分为未抗凝组75例和低分子量肝素60例或华法林39例的抗凝组。定性评估显示抗凝组77/99(78%)患者左室摄取评分为0或1分,高于未抗凝组的10/75(13%)(p<.001);半定量左室糖酵解总值和代谢体积抗凝组均低于未抗凝组(p<.0001)。结论认为长时间禁食联合非普通肝素抗凝药可最小化心脏葡萄糖代谢。
要点
- >12小时禁食后,抗凝组78%(77/99)患者左室18F-FDG摄取评分为0或1分,未抗凝组为13%(10/75)(p<.001)。
- 抗凝组左室糖酵解总值198,989±261,439低于未抗凝组802,649±468,442(p<.0001)。
- 抗凝组代谢体积57±48 cm³低于未抗凝组219±77 cm³(p<.0001)。
核心结论
- 长时间禁食联合非普通肝素抗凝药能够最小化心脏葡萄糖代谢。
- 数据证实了在PET扫描前影响心脏代谢模式的可能性,并拓宽了药物选择范围。
研究设计与样本
- 174例无心脏功能障碍和/或冠心病病史及临床证据的患者接受18F-FDG PET/CT研究,所有患者均>12小时禁食。
- 分为2组:组1未接受抗凝治疗(n=75);组2接受低分子量肝素(n=60)或华法林(n=39)治疗。
- 心脏18F-FDG摄取采用4分法定性评估,并以总左室糖酵解(LVG)和代谢体积(MV)半定量评估,勾画包含整个左室的等轮廓感兴趣体积(VOI)。
主要发现
- 定性评估左室18F-FDG摄取评分为0或1分(提示良好抑制)者:组1为10/75(13%),组2为77/99(78%)(p<.001)。
- 半定量评估组1的18F-FDG摄取高于组2:LVG为802,649±468,442 vs 198,989±261,439(p<.0001)。
- 半定量评估组1的MV高于组2:219±77 vs 57±48 cm³(p<.0001)。
- 对抗凝药物的亚组分析显示相似结果。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Whether anticoagulants other than unfractionated heparin are able to suppress cardiac PET uptake of 2-deoxy-2-[18F]-fluoro-D-glucose (18F-FDG) is unknown. METHODS: One-hundred-seventy-four patients without history and clinical evidence of cardiac dysfunction and/or coronary heart disease underwent a 18F-FDG PET/CT study. All patients were studied with a >12-hours fasting and divided into 2 groups: group-1 without anticoagulant therapy (n:75); group-2 patients on low molecular weight heparin (n:60) or warfarin therapy (n:39). Cardiac 18F-FDG uptake was estimated qualitatively using a 4-point scale and semiquantitatively as total LV glycolysis (LVG) and metabolic volume (MV), drawing isocontour volume of interest (VOI) including the whole LV. RESULTS: Qualitatively, LV 18-FDG uptake was scored 0 or 1, indicating a good suppression, in 10/75 (13%) patients of group-1 and 77/99 (78%) of group-2 (p < .001). Semiquantitatively, patients of group-1 showed higher values of 18-FDG uptake than patients of group-2, assessed as LVG (802,649 ± 468,442 vs 198,989 ± 261,439, p < .0001) or MV (219 ± 77 vs 57 ± 48 cm3, p < .0001). Subanalysis for anticoagulant drugs showed similar results. CONCLUSIONS: Prolonged fasting combined to anticoagulants other than unfractionated heparin is able to minimize glucose cardiac metabolism. Our data confirm previous observation on the possibility to influence the metabolic pattern of the heart before the PET scan and broadens the spectrum of pharmacological options.
引用
- Giorgetti A, Marras G, Genovesi D, et al. Effect of prolonged fasting and low molecular weight heparin or warfarin therapies on 2-deoxy-2-[18F]-fluoro-D-glucose PET cardiac uptake. J Nucl Cardiol. 2017. PMID: 28160263. doi:10.1007/s12350-017-0800-8
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。